Optimizing Anti–Myelin-Associated Glycoprotein and IgM-Gammopathy Testing for Neuropathy Treatment Evaluation
A cutoff of 10,000 BTU seems optimal for typical anti-MAG neuropathy while ≥1,500 BTU reduces the likelihood of immune-treatable CIDP. Mass-Fix improves IgM-gammopathy detection in anti-MAG and other IgM-gammopathy neuropathies. Patients with IgM-gammopathy lacking MAG antibodies show reduced treatment response.
Authors
- Marcus Vinícius Pinto (ORCID: https://orcid.org/0000-0002-9890-6657)
- Divyanshu Dubey (ORCID: https://orcid.org/0000-0001-6865-9045)
- Grace Swart (ORCID: https://orcid.org/0000-0003-0661-7776)
- Michelle L. Mauermann (ORCID: https://orcid.org/0000-0001-9619-7802)
- Shahar Shelly (ORCID: https://orcid.org/0000-0002-3585-1687)
- David Murray (ORCID: https://orcid.org/0000-0003-1720-335X)
- Stephen M. Ansell (ORCID: https://orcid.org/0000-0003-1244-6758)
- Michael Skolka (ORCID: https://orcid.org/0009-0006-5155-4371)
- Amy P. Gorsh
- James Triplett (ORCID: https://orcid.org/0000-0001-9402-1248)
- John R. Mills (ORCID: https://orcid.org/0000-0003-1025-4760)
- Christopher J. Klein (ORCID: https://orcid.org/0000-0002-4012-8856)
Institutions
- Mayo Clinic in Arizona (US)
Publication Details
- Journal
- Neurology
- Published
- 2024-11-05
- DOI
- https://doi.org/10.1212/wnl.0000000000210000
- Citations
- 7
- Primary Topic
- Peripheral Neuropathies and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 2.58